Table 1.

Immunotherapy approved for metastatic urothelial carcinoma (mUC).

Drug	Mechanism	Trial	Indications
Pembrolizumab	Anti PD-1	KEYNOTE-045 (second-line) KEYNOTE-052 (first-line)	Second-line: progression during or following platinum-based chemotherapy First-line: not eligible for platinum-based chemotherapy
Nivolumab	Anti PD-1	CheckMate-275	Second-line: progression during or following platinum-based chemotherapy
Avelumab	Anti PD-L1	JAVELIN	Second-line: progression during or following platinum-based chemotherapy Maintenance therapy after first line platinum-based chemotherapy
Atezolizumab	Anti PD-L1	IMvigor210	First-line: not eligible for cisplatin-based chemotherapy and tumors express PD-L1 ≥5% OR not eligible for any platinum-based therapy